1224 related articles for article (PubMed ID: 34186022)
21. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial.
Urva S; Coskun T; Loh MT; Du Y; Thomas MK; Gurbuz S; Haupt A; Benson CT; Hernandez-Illas M; D'Alessio DA; Milicevic Z
Lancet; 2022 Nov; 400(10366):1869-1881. PubMed ID: 36354040
[TBL] [Abstract][Full Text] [Related]
22. Achievement of glycaemic targets with weight loss and without hypoglycaemia in type 2 diabetes with the once-weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide: A post hoc analysis of the SURPASS-1 to -5 studies.
Lingvay I; Cheng AY; Levine JA; Gomez-Valderas E; Allen SE; Ranta K; Torcello-Gómez A; Thieu VT
Diabetes Obes Metab; 2023 Apr; 25(4):965-974. PubMed ID: 36514843
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.
Frias JP; Deenadayalan S; Erichsen L; Knop FK; Lingvay I; Macura S; Mathieu C; Pedersen SD; Davies M
Lancet; 2023 Aug; 402(10403):720-730. PubMed ID: 37364590
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.
Ahrén B; Masmiquel L; Kumar H; Sargin M; Karsbøl JD; Jacobsen SH; Chow F
Lancet Diabetes Endocrinol; 2017 May; 5(5):341-354. PubMed ID: 28385659
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens.
Frias JP; Nauck MA; Van J; Benson C; Bray R; Cui X; Milicevic Z; Urva S; Haupt A; Robins DA
Diabetes Obes Metab; 2020 Jun; 22(6):938-946. PubMed ID: 31984598
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial.
Mosenzon O; Blicher TM; Rosenlund S; Eriksson JW; Heller S; Hels OH; Pratley R; Sathyapalan T; Desouza C;
Lancet Diabetes Endocrinol; 2019 Jul; 7(7):515-527. PubMed ID: 31189517
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trial.
Johansen NJ; Dejgaard TF; Lund A; Schlüntz C; Frandsen CS; Forman JL; Wewer Albrechtsen NJ; Holst JJ; Pedersen-Bjergaard U; Madsbad S; Vilsbøll T; Andersen HU; Knop FK
Lancet Diabetes Endocrinol; 2020 Apr; 8(4):313-324. PubMed ID: 32135138
[TBL] [Abstract][Full Text] [Related]
28. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
Frías JP; Davies MJ; Rosenstock J; Pérez Manghi FC; Fernández Landó L; Bergman BK; Liu B; Cui X; Brown K;
N Engl J Med; 2021 Aug; 385(6):503-515. PubMed ID: 34170647
[TBL] [Abstract][Full Text] [Related]
29. Tirzepatide: A Review in Type 2 Diabetes.
France NL; Syed YY
Drugs; 2024 Feb; 84(2):227-238. PubMed ID: 38388874
[TBL] [Abstract][Full Text] [Related]
30. Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes: The SURPASS-6 Randomized Clinical Trial.
Rosenstock J; Frías JP; Rodbard HW; Tofé S; Sears E; Huh R; Fernández Landó L; Patel H
JAMA; 2023 Nov; 330(17):1631-1640. PubMed ID: 37786396
[TBL] [Abstract][Full Text] [Related]
31. Dose-response effects on HbA
Blüher M; Rosenstock J; Hoefler J; Manuel R; Hennige AM
Diabetologia; 2024 Mar; 67(3):470-482. PubMed ID: 38095657
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial.
Dandona P; Mathieu C; Phillip M; Hansen L; Griffen SC; Tschöpe D; Thorén F; Xu J; Langkilde AM;
Lancet Diabetes Endocrinol; 2017 Nov; 5(11):864-876. PubMed ID: 28919061
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of dapagliflozin in children and young adults with type 2 diabetes: a prospective, multicentre, randomised, parallel group, phase 3 study.
Tamborlane WV; Laffel LM; Shehadeh N; Isganaitis E; Van Name M; Ratnayake J; Karlsson C; Norjavaara E
Lancet Diabetes Endocrinol; 2022 May; 10(5):341-350. PubMed ID: 35378069
[TBL] [Abstract][Full Text] [Related]
34. MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study.
Ambery P; Parker VE; Stumvoll M; Posch MG; Heise T; Plum-Moerschel L; Tsai LF; Robertson D; Jain M; Petrone M; Rondinone C; Hirshberg B; Jermutus L
Lancet; 2018 Jun; 391(10140):2607-2618. PubMed ID: 29945727
[TBL] [Abstract][Full Text] [Related]
35. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.
Pratley R; Amod A; Hoff ST; Kadowaki T; Lingvay I; Nauck M; Pedersen KB; Saugstrup T; Meier JJ;
Lancet; 2019 Jul; 394(10192):39-50. PubMed ID: 31186120
[TBL] [Abstract][Full Text] [Related]
36. Safety and efficacy of once-weekly basal insulin Fc in people with type 2 diabetes previously treated with basal insulin: a multicentre, open-label, randomised, phase 2 study.
Frias J; Chien J; Zhang Q; Chigutsa E; Landschulz W; Syring K; Wullenweber P; Haupt A; Kazda C
Lancet Diabetes Endocrinol; 2023 Mar; 11(3):158-168. PubMed ID: 36758572
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial.
Laffel LM; Danne T; Klingensmith GJ; Tamborlane WV; Willi S; Zeitler P; Neubacher D; Marquard J;
Lancet Diabetes Endocrinol; 2023 Mar; 11(3):169-181. PubMed ID: 36738751
[TBL] [Abstract][Full Text] [Related]
38. Glycaemic control, body weight, and safety of tirzepatide versus dulaglutide by baseline glycated haemoglobin level in Japanese patients with type 2 diabetes: A subgroup analysis of the SURPASS J-mono study.
Osonoi T; Oura T; Hirase T
Diabetes Obes Metab; 2024 Jan; 26(1):126-134. PubMed ID: 37794628
[TBL] [Abstract][Full Text] [Related]
39. Metformin in women with type 2 diabetes in pregnancy (MiTy): a multicentre, international, randomised, placebo-controlled trial.
Feig DS; Donovan LE; Zinman B; Sanchez JJ; Asztalos E; Ryan EA; Fantus IG; Hutton E; Armson AB; Lipscombe LL; Simmons D; Barrett JFR; Karanicolas PJ; Tobin S; McIntyre HD; Tian SY; Tomlinson G; Murphy KE;
Lancet Diabetes Endocrinol; 2020 Oct; 8(10):834-844. PubMed ID: 32946820
[TBL] [Abstract][Full Text] [Related]
40. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.
Davies M; Færch L; Jeppesen OK; Pakseresht A; Pedersen SD; Perreault L; Rosenstock J; Shimomura I; Viljoen A; Wadden TA; Lingvay I;
Lancet; 2021 Mar; 397(10278):971-984. PubMed ID: 33667417
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]